v3.26.3
Interim condensed consolidated statement of changes in shareholders' equity (Parenthetical) - EUR (€)
6 Months Ended
Jun. 05, 2026
Jan. 23, 2026
Jan. 01, 2026
Jun. 30, 2026
Jun. 30, 2025
Issue of equity       € 103,197,000 [1] € 135,550,000 [2]
Transaction costs       (8,205,000) (7,519,000)
Share capital          
Issue of equity       430,000 [1] 435,000 [2]
Exercise of warrants       157,000  
Premiums related to share capital          
Issue of equity       123,899,000 [1],[3] 135,115,000 [2]
Exercise of warrants       21,100,000  
Transaction costs       € (8,205,000) [3] € (7,519,000)
Equity offering          
Number of shares issued during the period 27,272,727     27,272,727  
Transaction costs € (7,800,000)   € (7,800,000)    
Equity offering | Share capital          
Issue of equity 272,727     € 272,000  
Exercise of warrants 272,727        
Equity offering | Premiums related to share capital          
Issue of equity € 94,989,798     € 102,800,000  
Registered underwritten public offering          
Transaction costs     (400,000)    
Registered underwritten public offering | Share capital          
Transaction costs     (428,028)    
Registered underwritten public offering | Premiums related to share capital          
Transaction costs     € (400,000)    
Tranche II, 2024 Financing arrangement in three tranches | T2 BSA Prefunded Warrants          
Number of warrants issued         43,437,036
Tranche II, 2024 Financing arrangement in three tranches | T2 BSA Prefunded Warrants | Share capital          
Exercise of warrants   € 111,111      
Tranche II, 2024 Financing arrangement in three tranches | T2 BSA Prefunded Warrants | Premiums related to share capital          
Exercise of warrants   € 14,888,889      
T2 New Share | Tranche II, 2024 Financing arrangement in three tranches          
Number of shares issued during the period         42,488,883
[1] Share capital variation include a €272 thousand increase from the Equity Offering completed on June 5, 2026, corresponding to the issuance of 27,272,727 ordinary shares, and a €157 thousand increase in share capital resulting from the exercise of T1 and T2 warrants issued under the Structured Financing (see Note 4.8 – Shareholders’ equity).
[2] Corresponding mainly to the share capital increase consisting of the issuance of 42,488,883 new ordinary shares (see Note 4.8 Shareholders’ equity to the annual consolidated financial statements for the year ended on December 31, 2025)
[3] Premiums related to share capital include €102.8 million of share premium resulting from the Equity Offering and €21.1 million resulting from the exercise of T1 and T2 warrants issued under the Structured Financing and (€7.8) million of transaction costs related to the Equity Offering and (€0.4) million relating to transaction costs recognized on January 1, 2026 in connection with the November 2025 public offering (see Note 4.8 – Shareholders’ equity).